This review discusses the development and characteristics of allergic inflammation, focusing on the role of mast cells in allergic disorders. Allergic disorders, such as anaphylaxis, hay fever, eczema, and asthma, affect about 25% of people in the developed world. These conditions result from persistent or repeated exposure to allergens, which are typically harmless environmental substances. Allergic inflammation leads to long-term changes in affected organs and functional abnormalities. Understanding the features of acute and chronic allergic inflammation is important, particularly how mast cells contribute to this maladaptive immune response. The term 'allergy' was coined by Clemens von Pirquet in 1906 to highlight the unusual immune reactions to certain substances. Allergic disorders involve abnormal immune responses, often mediated by IgE and T helper 2 (Th2) cells. These disorders include allergic rhinitis, atopic dermatitis, allergic asthma, and some food allergies. Anaphylaxis, a potentially fatal systemic reaction, can occur within seconds or minutes after allergen exposure. Allergic inflammation is classified into early-phase, late-phase, and chronic phases. Early-phase reactions occur within minutes of allergen exposure and involve IgE-mediated responses leading to mediator release. Late-phase reactions develop 2-6 hours after exposure and are associated with immune cell recruitment and activation. Chronic allergic inflammation results from prolonged exposure and involves persistent immune cell infiltration and tissue changes. Mast cells play a key role in allergic inflammation by releasing mediators that cause vasodilation, increased vascular permeability, and tissue changes. These mediators also contribute to the recruitment and activation of immune cells, leading to late-phase reactions. Chronic allergic inflammation is associated with structural and functional changes in affected tissues, such as airway remodeling in asthma. The development of allergic disorders is influenced by genetic and environmental factors, including immune responses to parasites and the hygiene hypothesis. Allergen sensitization involves Th2-cell responses driven by IgE production. Epithelial barrier function is crucial in preventing allergen entry and can be affected by genetic mutations, such as those in the FLG gene. Allergic inflammation is managed through prevention of allergen exposure and treatment with therapeutic agents. Treatments include antihistamines, corticosteroids, and monoclonal antibodies targeting IgE. New approaches aim to improve immunological tolerance and prevent allergic sensitization. Understanding the complex interactions between immune cells and environmental factors is essential for developing effective therapies for allergic disorders.This review discusses the development and characteristics of allergic inflammation, focusing on the role of mast cells in allergic disorders. Allergic disorders, such as anaphylaxis, hay fever, eczema, and asthma, affect about 25% of people in the developed world. These conditions result from persistent or repeated exposure to allergens, which are typically harmless environmental substances. Allergic inflammation leads to long-term changes in affected organs and functional abnormalities. Understanding the features of acute and chronic allergic inflammation is important, particularly how mast cells contribute to this maladaptive immune response. The term 'allergy' was coined by Clemens von Pirquet in 1906 to highlight the unusual immune reactions to certain substances. Allergic disorders involve abnormal immune responses, often mediated by IgE and T helper 2 (Th2) cells. These disorders include allergic rhinitis, atopic dermatitis, allergic asthma, and some food allergies. Anaphylaxis, a potentially fatal systemic reaction, can occur within seconds or minutes after allergen exposure. Allergic inflammation is classified into early-phase, late-phase, and chronic phases. Early-phase reactions occur within minutes of allergen exposure and involve IgE-mediated responses leading to mediator release. Late-phase reactions develop 2-6 hours after exposure and are associated with immune cell recruitment and activation. Chronic allergic inflammation results from prolonged exposure and involves persistent immune cell infiltration and tissue changes. Mast cells play a key role in allergic inflammation by releasing mediators that cause vasodilation, increased vascular permeability, and tissue changes. These mediators also contribute to the recruitment and activation of immune cells, leading to late-phase reactions. Chronic allergic inflammation is associated with structural and functional changes in affected tissues, such as airway remodeling in asthma. The development of allergic disorders is influenced by genetic and environmental factors, including immune responses to parasites and the hygiene hypothesis. Allergen sensitization involves Th2-cell responses driven by IgE production. Epithelial barrier function is crucial in preventing allergen entry and can be affected by genetic mutations, such as those in the FLG gene. Allergic inflammation is managed through prevention of allergen exposure and treatment with therapeutic agents. Treatments include antihistamines, corticosteroids, and monoclonal antibodies targeting IgE. New approaches aim to improve immunological tolerance and prevent allergic sensitization. Understanding the complex interactions between immune cells and environmental factors is essential for developing effective therapies for allergic disorders.